InMed and the laboratory of Dr. Vikramaditya Yadav at the University of British Columbia collaborate on a proprietary biosynthesis technology to produce bioidentical, high purity, high grade cannabinoids. The host selected is E.coli. In this video, Dr. Yadav talks how an E.coli-based system is uniquely suited for producing cannabinoids.
InMed’s INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Promising early studies demonstrate INM-901’s neuroprotective effects and an ability